Vaccines
RFK Jr. attacks environmental toxins as cause of childhood autism ‘epidemic’, stays silent on vaccines
Autistic Disorder, Vaccines, Kennedy, Environment, RFK gene, HHS
HHS Terminates Funding for GeoVax’s Next-Generation COVID-19 Vaccine: Impacts and Developments
GeoVax, HHS, BARDA, Project NextGen, COVID-19 vaccine, GEO-CM04S1, clinical trials, funding termination, immunocompromised, vaccine development, pandemic preparedness
Former FDA Officials Sound Alarm: Visible Changes May Be Tip of the Iceberg
United States Food and Drug Administration, public health medicine (field), Changing, Vaccines, Leadership, Policy, drug safety, Previous, KAT5 wt Allele, Icebergs, Disease Outbreaks, Alarm device, Visible
CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s
Adult, Respiratory syncytial virus, Centers for Disease Control and Prevention (U.S.), Vaccines, Recommendation, Age, Arexvy, Chronic Condition, Severe (severity modifier), 50–59, broaden
Vaccine-probiotic combo prevents, clears bacterial gut infections in mice in antibiotic alternative test
Antibiotics, Probiotics, House mice, Immune response, Vaccines
Former CBER head Peter Marks says he blocked RFK Jr. from vaccine safety database before leaving FDA: AP
Vaccines, Massive, Vaccine Safety, Kennedy, United States Food and Drug Administration, RFK Jr., Disease Outbreaks, Peter Marks, VAERS, Kennedy ‘s
RFK Jr. promotes measles vaccine as Texas outbreak continues
Vaccines, Texas, Measles, Disease Outbreaks, Measles-Mumps-Rubella Vaccine, Case (situation), RFK gene, Effectiveness, Vaccination, Texas
Novavaxs held-up approval package may signal warning for Covid vaccine makers
Vaccines, Approved, COVID19 (disease), United States Food and Drug Administration, Market, Novavax ‘s, Maker (occupation), Deferred
FDA official said to step in and pause review of Novavax’s COVID-19 vaccine
United States Food and Drug Administration, COVID19 (disease), Vaccines, Novavax ‘s, Review [Publication Type], Novavax, Approved
Curevo Secures $110M for Advanced Shingles Vaccine Development
Curevo Vaccine, amezosvatein, shingles vaccine, Series B funding, improved tolerability, Shingrix competitor